Cardiovascular Health & Atherosclerosis Prevention Protocol
Cardiovascular Health & Atherosclerosis Prevention Protocol framework focused on consistent execution, practical monitoring, and safer progression.
Cardioprotective peptide protocol targeting endothelial function, plaque stabilization, myocardial protection, and reduction of cardiovascular inflammation in at-risk adults.
Who it's for
Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.
Free Peptide Guide
Cardiovascular Health & Atherosclerosis Prevention Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Protocol at a Glance
Cycle Duration
Continuous; minimum 16 weeks; monitor lipids and CRP every 8 weeks
Target Audience
Adults with cardiovascular risk factors, post-MI recovery, or family history of heart disease
| Compound | Dose | Frequency |
|---|---|---|
| SS-31 (Elamipretide) SS-31 — cardiac mitochondrial protection, reduced ischemia-reperfusion injury | 2 mg/kg SQ | Daily |
| Thymosin Beta-4 TB-500/Thymosin Beta-4 — coronary vessel regeneration, cardiac repair | 1.5 mg SQ | Daily |
| BPC-157 BPC-157 — vascular anti-inflammatory, blood pressure normalization | 250 mcg | 2x daily |
| Humanin Humanin — cardiomyocyte protection, plaque-associated inflammation | 2 mg SQ | Daily |
| Cortagen Cortagen — cardioprotection via HSP70/90 induction, apoptosis reduction | 1 mg SQ | Daily |
Free Peptide Guide
Cardiovascular Health & Atherosclerosis Prevention Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Daily Schedule
Morning
Baseline review and first execution window
Log sleep, energy, and tolerance; complete planned SS-31 (Elamipretide) timing if scheduled.
Midday
Adherence and symptom check
Review hydration, workload, and side effects before any changes.
Evening
Recovery closeout and next-day setup
Record outcomes, maintain schedule consistency, and prepare next-day protocol.
Safety
- Escalating side effects or new concerning symptoms require prompt clinical review.
- Avoid abrupt multi-compound changes during unstable periods.
- Maintain regular follow-up with a licensed clinician throughout the cycle.
Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.
Who should avoid
- Anyone using this protocol without qualified medical supervision
- People with unstable medical or psychiatric conditions without specialist guidance
- Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Common Mistakes
Changing multiple variables at once
Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.
How to fix: Keep one-variable changes per review cycle and log response for several days.
Ignoring adherence and recovery fundamentals
Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.
How to fix: Protect daily anchors first, then optimize protocol details gradually.
FAQ
How long should Cardiovascular Health & Atherosclerosis Prevention Protocol run before reassessment?
A common window is Continuous; minimum 16 weeks; monitor lipids and CRP every 8 weeks, with periodic review of tolerance and objective trends.
Can I increase complexity quickly for faster results?
Usually no. Safer optimization comes from staged changes and clear tracking.
What should I track each day?
Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.
Key Takeaways
- Consistency with SS-31 (Elamipretide) + Thymosin Beta-4 execution matters more than frequent protocol changes.
- Single-variable adjustments improve safety and decision quality.
- Objective daily tracking supports better long-term outcomes.
Why This Stack Works
Cardiovascular disease begins with endothelial dysfunction, oxidative LDL, and chronic low-grade inflammation. SS-31 protects cardiac mitochondria and reduces ischemic injury. TB-500 promotes coronary vessel regeneration. BPC-157 normalizes blood pressure and reduces vascular inflammation. Thymosin Alpha-1 reduces inflammatory monocyte activation in atherosclerotic plaques. Humanin reduces cardiac amyloid and protects cardiomyocytes.
Clinical Research
No clinical references were provided for this stack yet.
More Cardiovascular Health Stacks
Cardiac Health & Heart Peptide Protocol
Comprehensive cardiac protection stack combining GH secretagogue-mediated cardioprotection, peptide cytoprotection, mitochondrial preservation, and tissue-protective receptor activation.
Heart Failure & Cardiac Rehabilitation Protocol
A comprehensive adjunctive protocol for heart failure patients and cardiac rehabilitation participants, targeting myocardial energetics, cardiac fibrosis, vascular function, and the autonomic dysregulation that perpetuates heart failure progression.
Peripheral Artery Disease (PAD) & Vascular Repair Protocol
A protocol for patients with peripheral artery disease targeting therapeutic angiogenesis, collateral vessel development, ischemic muscle protection, and peripheral vasodilation to improve walking distance and limb perfusion.
Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.
Free Peptide Guide
Cardiovascular Health & Atherosclerosis Prevention Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.